Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
- The platform is designed to detect cocaine, cannabis, alcohol, narcotics, psychedelics, and human fatigue using voice analysis and artificial intelligence.
- MindBio is preparing to deploy the software through Edge AI kiosk systems targeted at safety-critical industries.
- The company is pursuing commercialization opportunities in mining, aviation, construction, transportation, and law enforcement markets.
- MindBio’s technology offers a non-invasive and affordable alternative to traditional drug and alcohol testing methods.
- The launch represents a key step in the company’s transition from research and clinical development toward commercial implementation.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, has launched Intox AI(TM), its flagship enterprise software platform designed to detect drug use, alcohol intoxication, and human fatigue, through voice analysis powered by artificial intelligence. The announcement marks an important milestone in the company’s commercialization strategy as it moves toward deployment of its first Edge AI kiosk prototypes, which are expected to be completed during the current quarter (https://ibn.fm/GrITB).
According to MindBio, Intox AI(TM) is designed to analyze speech patterns in real time and identify indicators associated with multiple neurologically active substances, including cocaine, cannabis, alcohol, psychedelics, and narcotics. The platform is also being developed to assess human fatigue, a factor that remains a significant safety concern in many industrial environments.
The company believes the technology could address a growing need for scalable impairment screening in industries where worker alertness and sobriety are essential. Mining operations, aviation, construction, heavy transportation, and law enforcement, are among the sectors being targeted for future commercialization. These industries often operate under strict workplace safety requirements and regulatory frameworks that mandate drug and alcohol testing programs.
Traditional testing methods typically rely on breathalyzers, saliva tests, or laboratory analysis, approaches that can be time-consuming, require specialized equipment, involve ongoing consumable costs, and create operational challenges when screening large numbers of workers.
MindBio’s approach seeks to simplify that process by using voice as the primary diagnostic input. The company’s system analyzes millions of data points extracted from speech and generates an assessment within seconds. When scaled, such a platform could offer organizations a much faster and less intrusive screening method than many existing alternatives.
The launch of Intox AI(TM) builds on several years of research and development focused on acoustic biomarkers. MindBio has been conducting clinical studies examining how intoxication and impairment affect speech characteristics. Through those studies, the company has developed machine-learning models designed to identify measurable changes in voice patterns associated with substance use and cognitive impairment.
According to the company, its predictive models have been trained on more than 50 million data points and analyze over 140 acoustic parameters extracted from human speech. Management states that this dataset has helped establish a proprietary foundation for both consumer and enterprise applications.
The company’s technology portfolio now extends beyond alcohol detection alone. MindBio previously introduced Booze AI, a consumer-focused application that estimates blood alcohol concentration using voice analysis and behavioral inputs. Intox AI(TM) expands those capabilities into enterprise markets while adding detection capabilities across multiple substance categories and fatigue-related conditions.
The company is pursuing a business model that combines hardware deployment with recurring software revenue. Its Edge AI kiosks are being designed for on-site use in industrial environments, enabling workers to complete voice-based assessments through touchless systems that perform analysis locally and provide compliance-ready reporting.
Beyond workplace safety, management has identified potential future applications in telehealth, remote monitoring, and broader health prediction technologies. Because the underlying platform analyzes physiological and cognitive indicators reflected in speech, the company believes its technology may be adaptable across multiple healthcare and wellness use cases.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
